Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3

Background/Aim: Immune check-point inhibitors are often unsuitable for patients with urothelial cancer with a poor performance status (PS 2 or 3). The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcitabine and paclitaxel every 4 weeks. Patients and Me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:In Vivo
Main Authors: ARAKI, KYOHEI, MIYATA, YASUYOSHI, NAKAMURA, YUICHIRO, MUKAE, YUTA, OTSUBO, ASATO, YUNO, TSUTOMU, MITSUNARI, KENSUKE, MATSUO, TOMOHIRO, OHBA, KOJIRO, SAKAI, HIDEKI
Formato: Artigo
Idioma:Inglês
Publicado em: International Institute of Anticancer Research 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899086/
https://ncbi.nlm.nih.gov/pubmed/31662559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados